ACUMEN PHARMACEUTICALS INC. - COMMON STOCK

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

02 Apr 2025 06:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

27 Mar 2025 06:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

26 Mar 2025 07:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

20 Mar 2025 15:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

19 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

12 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

10 Mar 2025 15:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

09 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

26 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

12 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

11 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

06 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024

05 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference

31 Oct 2024 07:05:25 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

23 Oct 2024 07:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

30 Sep 2024 15:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease

26 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

25 Sep 2024 15:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

03 Sep 2024 15:00:00 By Nasdaq GlobeNewswire